

**IN THE CLAIMS**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Currently amended) ~~The method of claim 1 wherein the endothelin antagonist is~~ A method of ameliorating Alzheimer's disease comprising administering to a human suffering from Alzheimer's disease a therapeutically effective amount of bosentan.
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Currently amended) The method of claim ~~1~~ 9 further comprising administering a therapeutically effective amount of a cholinesterase inhibitor useful in ~~the~~ a medical therapeutic treatment of Alzheimer's disease.
14. (Cancelled)
15. (Previously presented) The method of claim 13 wherein the cholinesterase inhibitor is selected from the group consisting of tacrine, metrifonate, bethanacol, physostigmine, donepezil, rivastigmine, galantamine, and mixtures thereof.
16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Currently amended) The method of claim 13 wherein the ~~endothelin~~  
~~antagonist~~ bosentan and the cholinesterase inhibitor are administered simultaneously.

20. (Currently amended) The method of claim 13 wherein the ~~endothelin~~  
~~antagonist~~ bosentan and the cholinesterase inhibitor are administered from a single  
composition.

21. (Currently amended) The method of claim 13 wherein the ~~endothelin~~  
~~antagonist~~ bosentan and the cholinesterase inhibitor are administered from separate  
compositions.

22. (Currently amended) The method of claim 13 wherein the ~~endothelin~~  
~~antagonist~~ bosentan and the cholinesterase inhibitor are administered separately.

23. (Currently amended) The method of claim 22 wherein the ~~endothelin~~  
~~antagonist~~ bosentan is administered prior to the cholinesterase inhibitor.

24. (Currently amended) The method of claim 22 wherein the ~~endothelin~~  
~~antagonist~~ bosentan is administered after the cholinesterase inhibitor.

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (New) The method of claim 9 wherein the bosentan is administered  
orally or parenterally.

32. (New) The method of claim 9 wherein the therapeutically effective amount of bosentan is about 0.1 to about 50 mg for a 70 kg adult.

33. (New) The method of claim 20 wherein the single composition is in the form of a tablet, a capsule, or a powder.